Polly A. Murphy Net Worth

The estimated Net Worth of Polly A. Murphy is at least $207 mil dollars as of 16 June 2024. Polly Murphy owns over 33,150 units of Atea Pharmaceuticals stock worth over $207,153 and over the last 3 years Polly sold AVIR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Polly Murphy AVIR stock SEC Form 4 insiders trading

Polly has made over 3 trades of the Atea Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently Polly exercised 33,150 units of AVIR stock worth $121,661 on 16 June 2024.

The largest trade Polly's ever made was exercising 33,150 units of Atea Pharmaceuticals stock on 16 June 2024 worth over $121,661. On average, Polly trades about 5,015 units every 91 days since 2021. As of 16 June 2024 Polly still owns at least 56,445 units of Atea Pharmaceuticals stock.

You can see the complete history of Polly Murphy stock trades at the bottom of the page.

What's Polly Murphy's mailing address?

Polly's mailing address filed with the SEC is 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110.

Insiders trading at Atea Pharmaceuticals

Over the last 4 years, insiders at Atea Pharmaceuticals have traded over $279,832 worth of Atea Pharmaceuticals stock and bought 553,666 units worth $13,102,824 . The most active insiders traders include Andrew A. F. Hack, Franklin M Berger, eSprings Capital Management .... On average, Atea Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $229,012. The most recent stock trade was executed by Bruce Polsky on 20 June 2024, trading 17,544 units of AVIR stock currently worth $61,229.

What does Atea Pharmaceuticals do?

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Complete history of Polly Murphy stock trades at Celcuity Inc e Atea Pharmaceuticals

Atea Pharmaceuticals executives and stock owners

Atea Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Jean-Pierre Sommadossi Ph.D.,
  Founder, Chairman, CEO & Pres
• Dr. Janet M.J. Hammond M.D., Ph.D.,
  Chief Devel. Officer
• Dr. Maria Arantxa Horga M.D.,
  Chief Medical Officer
• Andrea J. Corcoran,
  CFO, Exec. VP of Legal & Sec.
• Ariyapadi N. Krishnaraj,
  VP of Marketing
• Wayne Foster C.P.A., CPA,
  Exec. VP & Chief Accounting Officer
• Andrea J. Corcoran J.D.,
  CFO, Exec. VP of Legal & Sec.
• Dr. Janet M.J. Hammond,
  Chief Devel. Officer
• John F. Vavricka,
  Chief Commercial Officer
• Xiao-Jian Zhou Ph.D.,
  Exec. VP of Early Stage Devel.
• Adel Moussa Ph.D.,
  Exec. VP of Chemistry
• Steven Good,
  Exec. VP of Preclinical Science
• Paul J. Fanning,
  Sr. VP of HR
• Jonae R. Barnes,
  Sr. VP of Investor Relations & Corp. Communications
• Wayne Foster CPA, CPA,
  Sr. VP of Fin. & Admin.
• Asset Management, Lp Chen B...,
  
• Springs Capital Management ...,
  
• Isaac Cheng,
  Director
• Chung K. Chu,
  10% owner
• Barbara Gayle Duncan,
  
• Bruno Lucidi,
  
• Franklin M Berger,
  
• Polly A. Murphy,
  
• Bruce Polsky,
  
• Wayne Foster,
  EVP, Chief Accounting Officer
• Janet Mj Hammond,
  Chief Development Officer
• Jean Pierre Sommadossi,
  President, CEO, and Chairman
• Maria Arantxa Horga,
  Chief Medical Officer
• Andrea Corcoran,
  See Remarks
• John Vavricka,
  Chief Commercial Officer